Tel.: +91 22 66782800 FAX: +91 22 66782828 / 66782808

E-mail: office@shardaintl.com

Regd. Office: Prime Business Park, Dashrathlal Joshi Road, Vile Parle (W), Mumbai - 400056, India. www.shardacropchem.com





October 26, 2021

The Secretary **BSE Limited** Listing Department Phiroze Jeejeebhoy Towers Dalal Street, Mumbai - 400 001

Scirp Code: 538666 Scrip ID: SHARDACROP

Subject: Investors/Analyst's Presentation for the quarter and half year ended September 30, 2021

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), we are enclosing herewith the presentation to be made to the Investors/Analysts on the Financial Results of the Company for the quarter and half year ended September 30, 2021.

The presentation is also being uploaded on the website of the Company www.shardacropchem.com in accordance with Regulation 46 of the Listing Regulations.

We request you to take the same on record.

Yours faithfully,

Jetkin Gudhka Company Secretary & Compliance Officer

Encl: As above

Sharda Cropchem Limited
INVESTOR PRESENTATION
Q2 & H1 FY22 Results Update



Sharda Cropchem Limited







PAGE NO.	CONTENTS
03	Q2 & H1 FY22 RESULT HIGHLIGHTS
13	FINANCIAL PERFORMANCE
18	COMPANY OVERVIEW
23	BUSINESS MODEL
25	BUSINESS STRATEGY & OUTLOOK










Q2 & H1 FY22 Result Highlights







Revenues grew by 51.3% YoY to ₹ 6,428 mn in Q2 FY22 led by strong volume growth across geographies

Gross profit grew by 36.3% YoY to ₹ 1,798 mn in Q2 FY22. Gross margin during Q2 FY22 stood at 28.0% **EBITDA** grew by 76.8% YoY from ₹ 587 mn in Q2 FY21 to ₹ 1,038 mn in Q2 FY22

EBITDA margin expanded by 233bps YoY to 16.1% in Q2 FY22 driven by volume growth and better cost management, partly impacted by change in product mix and inflation in the freight cost.


PBT grew by 37.3% YoY from ₹ 302 mn in Q2 FY21 to ₹ 415 mn in Q2 FY22, partly impacted by higher depreciation charge and forex loss in Q2 FY22 vis-à-vis forex gain in Q2 FY21

PAT surged by 67.9% YoY from ₹ 191 mn in Q2 FY21 to ₹ 320 mn in Q2 FY22

PAT margin expanded by 49bps YoY to 5.0% in Q2 FY22 mainly due to lower effective tax rates (22.9% in Q2 FY22 vs. 36.9% in Q2 FY21)

^{*} EBITDA excluding IA & IAUD write-off (₹ 8.7 mn in Q2 FY22 and ₹ 19.2 mn in Q2 FY21) (IA & IAUD – Intangible Assets & Intangible Assets Under Development)





Revenues grew by 55.5% YoY to ₹ 12,655 mn in H1 FY22 led by strong volume growth across geographies

Gross profit grew by 46.0% YoY to ₹ 3,624 mn in H1 FY22. Gross margin during H1 FY22 stood at 28.6% **EBITDA** grew by 96.1% YoY from ₹ 1,073 mn in H1 FY21 to ₹ 2,104 mn in H1 FY22

EBITDA margin expanded by 344bps YoY to 16.6% in H1 FY22 driven by volume growth and better cost management, partly impacted by change in the product mix and inflation in the freight cost. PBT grew by 66.3% YoY from ₹ 649 mn in H1 FY21 to ₹ 1,080 mn in H1 FY22 led by better operating leverage ,partly impacted higher depreciation & forex loss in H1FY22 vs forex gain in FY21.

PAT surged by 49.2% YoY from ₹ 470 mn in H1 FY21 to ₹ 701 mn in H1 FY22


PAT margin contracted by 24bps YoY to 5.5% in H1 FY22 mainly due to higher effective tax rates (35.1% in H1 FY22 vs. 27.6% in H1 FY21)


^{*} EBITDA excluding IA & IAUD write-off (₹ 44.1 mn in H1 FY22 and ₹ 29.6 mn in H1 FY21) (IA & IAUD – Intangible Assets & Intangible Assets Under Development)



Q2 FY22 REGIONWISE REVENUE BRIDGE

H1 FY22 REGIONWISE REVENUE BRIDGE






 NAFTA, Europe & LATAM continues to be the growth engine for Sharda Cropchem




Q2 FY22 YoY ANALYSIS: REVENUE BREAKUP



- Agrochemicals revenues during Q2 FY22 grew by 46.1% YoY
- ➤ Non-Agrochemicals revenues during Q2 FY22 grew by 73.8% YoY
- ➤ Revenue Mix:
 Agrochemicals: Non-Agrochemicals mix stood at 78:22 in Q2 FY22 as against 81:19 in Q2 FY21

H1 FY22 YoY ANALYSIS: REVENUE BREAKUP





- Agrochemicals revenues during H1 FY22 grew by 59.2% YoY
- Non-Agrochemicals revenues during H1 FY22 grew by 40.7% YoY
- Revenue Mix: Agrochemicals : Non-Agrochemicals mix stood at 82:18 in H1 FY22 as against 80:20 in H1 FY21

Q2 FY22: AGROCHEMICALS BUSINESS DEEP DIVE










- Q2 FY22 Revenue Growth:
 Europe: 0.6%, NAFTA: 124.4%,
 LATAM 134.8% & RoW: 85.9%
- Formulation: Al MixQ2 FY22 94:6Q2 FY21 93:7


Product Mix updates: Herbicides continues to command 52.0% of revenues in Q2 FY22 & 51.0% of revenues in Q2 FY21

H1 FY22: AGROCHEMICALS BUSINESS DEEP DIVE











H1 FY22 Revenue Growth: Europe: 25.8%, NAFTA: 110.8%, LATAM 120.3% & RoW: 44.9%



Formulation: Al MixH1 FY22 – 92:8H1 FY21 – 93:7



Product Mix updates: Herbicides continues to command 49.7% of revenues in H1 FY22 & 49.8% of revenues in H1 FY21



REVENUE BREAKUP: REGIONWISE

Q2 FY21: Non-Agrochemicals Revenues: 805

[16%]
[45%]
[31%]

RoW, 131

[8%]

NAFTA, 358

Europe, 251

LATAM, 65

Q2 FY22: Non-Agrochemicals Revenues : 1,399



- ➤ NAFTA grew by 95.9% in Q2 FY22 to ₹ 702 mn
- ➤ Europe grew by 64.7% in Q2 FY22 to ₹ 413 mn
- ➤ RoW grew by 58.9% in Q2 FY22 to ₹ 207 mn
- ➤ LATAM grew by 17.5% in Q2 FY22 to ₹ 77 mn



REVENUE BREAKUP: REGIONWISE

H1 FY21: Non-Agrochemicals Revenues : 1,622

[17%]
[43%]
[34%]


RoW,
279

NAFTA, 699

Europe, 549

LATAM, 95

H1 FY22: Non-Agrochemicals Revenues : 2,282





- ➤ NAFTA grew by 55.8% in H1 FY22 to ₹ 1,088 mn
- ➤ Europe grew by 19.3% in H1 FY22 to ₹ 655 mn
- ➤ RoW grew by 47.8% in H1 FY22 to ₹ 412 mn
- ➤ LATAM grew by 33.7% in H1 FY22 to ₹ 127 mn



WORKING CAPITAL DAYS*

NET WORKING CAPITAL DAYS





> Net working capital days improved to 86 days in H1 FY22 as against 98 days in H1 FY21



Financial Performance





Particulars	Q2 FY22	Q2 FY21	YoY %	H1 FY22	H1 FY21	YoY %	FY21
Revenue from Operations	6,427.8	4,247.6	51.3%		8,136.6	55.5%	23,956.1
cogs	,	·		•	,		•
	4,629.4	2,927.7	58.1%	9,030.8	5,655.1	59.7%	16,359.6
Gross Profit	1,798.4	1,319.9	36.3%	3,623.7	2,481.5	46.0%	7,596.5
Gross Margin %	28.0%	31.1%	(309bps)	28.6%	30.5%	(186bps)	31.7%
Employee Expenses	105.4	74.2	42.2%	205.9	158.0	30.3%	373.2
Other Expenses	663.9	678.0	(2.1%)	1,358.1	1,280.3	6.1%	3,054.8
EBITDA*	1,037.9	587.0	76.8%	2,103.8	1,072.8	96.1%	4,551.7
EBITDA Margin %	16.1%	13.8%	233bps	16.6%	13.2%	344bps	19.0%
Forex (Gain)/Loss	131.8	(70.3)	N.A.	16.9	(204.9)	N.A.	(198.9)
Depreciation	606.4	423.2	43.3%	1,145.6	777.8	47.3%	1,704.4
Finance Cost	4.4	7.3	(39.5%)	10.5	15.6	(32.6%)	27.7
Other Income	128.5	94.7	35.7%	193.1	194.4	(0.6%)	459.3
PBT	415.1	302.3	37.3%	1,079.8	649.1	66.3%	3,094.5
Tax Expense	94.9	111.5	(14.9%)	378.9	179.2	111.4%	802.3
PAT	320.2	190.7	67.9%	700.9	469.9	49.2%	2,292.2
PAT Margin %	5.0%	4.5%	49bps	5.5%	5.8%	(24bps)	9.6%
Earnings Per Share (EPS) In ₹	3.55	2.11	68.2%	7.77	5.20	49.4%	25.40

^{*} EBITDA excluding IA & IAUD write-off (₹ 8.7 mn in Q2 FY22, ₹ 19.2 mn in Q2 FY21, ₹ 44.1 mn in H1 FY22, ₹ 29.6 mn in H1 FY21 and ₹ 383.2 mn in FY21) (IA & IAUD – Intangible Assets & Intangible Assets Under Development)

H1 FY22: CONSOLIDATED BALANCE SHEET



In ₹ Mn

Particulars	H1 FY22	FY21	Particulars	H1 FY22	FY21
Equities & Liabilities			Assets		
Shareholder's Funds			Non-Current Assets		
Equity and Share Capital	902.2	902.2	Property, Plant and Equipment	178.5	208.8
Other Equity	15,729.8	15,240.8	Goodwill	4.3	4.3
Non-controlling Interest	3.2	3.1	Other Intangible assets		
Total Equity	16,635.2	16,146.1	_	4,989.6	5,231.1
			Intangible assets under development	1,884.0	1,310.4
Non-Current Liabilities			Deferred Tax Assets (net)	47.4	60.4
Borrowings	-	-	Non-Current Tax Assets	699.3	736.3
Trade Payables	24.3	24.0	Other financial assets	124.1	94.0
Other Financial Liabilities	78.0	116.0	Total non-current assets	7,927.2	7,645.3
Provisions	23.1	30.2		.,	.,
Deferred Tax Liabilities (net)	1,012.9	928.7	Current Assets		
Total non-current liabilities	1,138.3	1,098.9		0.070.0	- 0
			Inventories	6,078.9	5,255.5
Current Liabilities			Investments	1,700.3	830.1
Borrowings	290.5	678.5	Trade Receivables	8,256.6	11,625.7
Trade Payables	5,743.9	8,067.5	Cash & Cash equivalents	1,087.7	855.5
Other Financial Liabilities	1,756.8	1,490.6	Other Bank balances	1,203.2	1,749.8
Other Current Liabilities	793.1	625.4	Other Financial Assets	162.2	280.6
Current Tax Liabilities	29.4	31.7	Other Current Assets	_	
Provisions	535.1	500.0		506.2	396.1
Total current Liabilities	9,148.8	11,393.6	Total current assets	18,995.1	20,993.3
Total Equity & Liabilities	26,922.3	28,638.6	Total Assets	26,922.3	28,638.6



Company Overview



COMPANY'S SNAPSHOT



Agrochemicals Focused Company

Intellectual Property (IP) driven company engaged in marketing and distribution of wide range formulations and generic active ingredients

Asset-Light Business Model

The Company efficiently channelises its time and resources for strengthening its core competency of identifying generic molecules and registration opportunities which offers scalable growth with limited capital requirements

Firm Registration Pipeline

The Company has procured 2,610 registrations* [2,324 registrations - Formulations and 286 registrations - Active Ingredients (AIs)]. Additionally, it has filed 1,054 applications for registrations globally pending at different stages

*As on 30th September, 2021

Diversified Sourcing Arrangements

Enduring relationship with multiple manufacturers and formulators enables the Company to source and supply formulations or generic active ingredients at competitive prices

Consistently Increasing Global Presence

With its diversified range of product portfolio, the Company has grown by expanding its business operations in 80+ countries, across Europe, NAFTA, Latin America and Rest of the World

Wide-spread Distribution Network

Presence in the entire agrochemical value chain with 500 third-party distributors and 400+ sales force serving the Company's esteemed clientele in 80+ countries

Prudent and Professional Management

The Company's apt domain knowledge and experience gives a substantial competitive advantage for expanding its business in existing markets and entering new geographies

Sound Financial Standing

Sharda Cropchem is a debt-free company which enables the Company to utilise its cash flows prudently

Financial Performance

Sales – 14.4% (FY17-21 CAGR) ROCE – 16.0% (FY21), ROE – 15.2% (FY21) and Net Cash & Cash Equivalents - INR 3,435 mn (FY21)

GEOGRAPHICAL FOOTPRINTS









KEY FINANCIAL PERFORMANCE INDICES






In ₹ Mn









PAT & PAT Margin

* EBITDA excluding IA & IAUD write-off





Source: PAT Margin = PAT / Revenue from Operations, EBITDA Margin = EBITDA / Revenue from Operations, ROE: PAT/Avg. Equity, ROCE: EBIT/Avg. Capital Employed [(Capital Employed = Equity + Total Debt)]

SHAREHOLDING STRUCTURE



KEY INSTITUTIONAL INVESTORS – 30 TH SEP 2021	% HOLDING
HDFC MF	9.20%
DSP MF	2.89%
L & T Mutual Fund	1.45%

SHAREHOLDING - 30TH SEP 2021

MARKET DATA	AS ON 22 ND OCT 2021
Market capitalization (INR Mn)	28,058.6
Price (INR)	311.0
No. of shares outstanding (Mn)	90.2
Face Value (INR)	10.0
52 week High-Low (INR)	387.1 – 230.8

Public 10.74% 13.55% FII 0.89% Promoter 74.82%



Source: BSE



Business Model





Agrochemical Value Chain

Sharda's Operating Area

Basic & Applied Research

Identification

Registration


Active Ingredient Manufacturing

Formulation & Packaging


Marketing & Distribution

ASSET LIGHT BUSINESS MODEL

- Focus on identification of generic molecules, preparing dossiers, seeking registrations, marketing & distributing formulations through third party distributors and/or own sales
- > Manufacturing of Als and formulations is outsourced
- ➤ Highly flexible operating model resulting in
 - Overall cost competitiveness
 - ➤ Efficient management of fluctuating market demand across various geographies.
 - Offering wide range of formulations and Als







Sharda is a focussed global agrochemical marketing & distribution company



Business Strategy & Outlook



BUSINESS STRATEGY & OUTLOOK





Expand & Strengthen Distribution Presence

- > Expand geographical reach using existing library of dossiers
- Two-fold strategy of further penetrating existing markets and entering new markets

Continual Investment in Product Registrations

- > Continue to identify generic molecules going off-patent
- > Investing in preparing dossiers and seeking registrations in own name

Focus on Operational Efficiencies

- Accelerated focus on revenue generating investments
- Margin improvements

02

03

04

Better cost management and eliminate NVAs

FOR FURTHER QUERIES



